<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03955666</url>
  </required_header>
  <id_info>
    <org_study_id>PRV-3279-1b</org_study_id>
    <nct_id>NCT03955666</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of PRV-3279 in Healthy Subjects</brief_title>
  <acronym>PREVAIL1</acronym>
  <official_title>PREVAIL 1: A Phase 1b, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of PRV-3279 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Provention Bio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Provention Bio, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1b study will evaluate the safety of PRV-3279 in healthy adult subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRV-3279-1b is a Phase 1b, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to
      Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of
      PRV-3279 in Healthy Subjects.

      Eligible subjects include healthy male or female adults, 18 to 50 years of age. Each subject
      will receive the assigned treatment over 29 days followed by a 56-day follow-up period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 7, 2019</start_date>
  <completion_date type="Actual">December 11, 2019</completion_date>
  <primary_completion_date type="Actual">December 11, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Double-blind, placebo-controlled, multiple ascending dose study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>85 days</time_frame>
    <description>Assessment of safety and tolerability</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Safety</condition>
  <arm_group>
    <arm_group_label>Cohort A (PRV-3279 or placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sterile solution for intravenous administration, 3 doses, every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B (PRV-3279 or placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sterile solution for intravenous administration, 3 doses, every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PRV-3279 or placebo</intervention_name>
    <description>bi-specific antibody-based molecule</description>
    <arm_group_label>Cohort A (PRV-3279 or placebo)</arm_group_label>
    <arm_group_label>Cohort B (PRV-3279 or placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy subjects as determined by no clinically significant deviation from normal in
             medical history, physical examination, ECGs, and clinical laboratory determinations.

          2. Body mass index (BMI) 18 to 32 kg/m2, inclusive.

          3. Male or female 18 to 50 years of age, inclusive.

          4. Nonpregnant women of childbearing potential (WOCBP) and sexually active men must agree
             to use effective birth control with male contraception during study participation
             through at least 3 months after the final dose. Women of non-childbearing potential
             may participate.

        Exclusion Criteria:

          1. Women who are pregnant or breastfeeding.

          2. Evidence of active or chronic infections.

          3. Previous exposure to PRV-3279.

          4. Any reason that, in the opinion of the Investigator, would contraindicate the
             subject's participation in the study or confound the results of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer</last_name>
    <role>Study Director</role>
    <affiliation>Provention Bio, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>May 16, 2019</study_first_submitted>
  <study_first_submitted_qc>May 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2019</study_first_posted>
  <last_update_submitted>December 19, 2019</last_update_submitted>
  <last_update_submitted_qc>December 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

